← Back to Screener
BriaCell Therapeutics Corp. Warrant (BCTXW)
Price$0.00
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-105.40%
Price vs S&P 500 (4W)-89.84%
VGM Score0.43
All Metrics
Price vs S&P 500 (YTD)-99.19%
10-Day Avg Trading Volume0.08M
3-Month Avg Trading Volume0.09M
52-Week High$0.11
26-Week Price Return-96.94%
13-Week Price Return-98.34%
3-Month Return Std Dev261.96%
Year-to-Date Return-98.30%
5-Day Price Return-67.86%
Month-to-Date Return-90.91%
Price vs S&P 500 (13W)-102.94%
Beta0.40x
52-Week Low$0.00
mGradeF
vgmGradeF
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCTXWBriaCell Therapeutics Corp. Warrant | — | — | F | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
BriaCell Therapeutics is a clinical-stage biotechnology company developing targeted cancer immunotherapies. The company's lead program, Bria-IMT, is a cell-based immunotherapy in late-stage clinical trials for breast cancer, while Bria-OTS is a personalized off-the-shelf immunotherapy platform for breast and prostate cancer. BriaCell is actively exploring combination therapy approaches through clinical collaborations to enhance treatment efficacy.